期刊
JOURNAL OF DIABETES
卷 14, 期 7, 页码 476-484出版社
WILEY
DOI: 10.1111/1753-0407.13296
关键词
diabetes mellitus; type 1; glucose; glycemic control
资金
- National Key Research and Development Program of China [2017YFC1309600]
- Science and Technology Planning Project of Guangzhou [202102010154]
This study explored the differences in glycemic metrics between FreeStyle Libre and iPro2 in adults with type 1 diabetes mellitus. The results showed that these two devices provided different estimations on time in range, coefficient of variation, and hypoglycemia-related parameters during the 14-day period of use.
Background Continuous glucose monitoring systems have been widely used but discrepancies among various brands of devices are rarely discussed. This study aimed to explore differences in glycemic metrics between FreeStyle Libre (FSL) and iPro2 among adults with type 1 diabetes mellitus (T1DM). Methods Participants with T1DM and glycosylated hemoglobin of 7%-10% were included and wore FSL and iPro2 for 2 weeks simultaneously. Datasets collected on the insertion and detachment day, and those with insufficient quantity (<90%) were excluded. Agreements of measurement accuracy and glycemic metrics were evaluated. Results A total of 40 498 paired data were included. Compared with the values from FSL, significantly higher median value was observed in iPro2 (147.6 [106.2, 192.6] vs. 144.0 [100.8, 192.6] mg/dl, p < 0.001) and the largest discordance was observed in hypoglycemic range (median absolute relative difference with iPro2 as reference value: 25.8% [10.8%, 42.1%]). Furthermore, significant differences in glycemic metrics between iPro2 and FSL were also observed in time in range (TIR) 70-180 mg/dl (TIR, 62.8 +/- 12.4% vs. 58.8 +/- 12.3%, p = 0.004), time spent below 70 mg/dl (4.4 [1.8, 10.9]% vs. 7.2 [5.4, 13.3]%, p < 0.001), time spent below 54 mg/dl (0.9 [0.3, 4.0]% vs. 2.6 [1.3, 5.6]%, p = 0.011), and coefficient of variation (CV, 38.7 +/- 8.5% vs. 40.9 +/- 9.3%, p = 0.017). Conclusions During 14 days of use, FSL and iPro2 provided different estimations on TIR, CV, and hypoglycemia-related parameters, which needs to be considered when making clinical decisions and clinical trial designs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据